Royal Bank of Canada’s Avalo Therapeutics AVTX Stock Holding History

Royal Bank of Canada’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26K	Buy	1,365 +1,149	+532%	+$18.2K	﹤0.01%	6161
2026 Q1	$2K	Buy	+216	New	+$3.38K	﹤0.01%	6666
2025 Q2	–	Sell	-212	Closed	-$2K	–	7014
2025 Q1	$2K	Sell	212 -117,144	-100%	-$888K	﹤0.01%	6548
2024 Q4	$872K	Buy	+117,356	New	+$1.25M	﹤0.01%	3667
2024 Q3	–	Sell	-590	Closed	-$7K	–	6836
2024 Q2	$7K	Buy	590 +268	+83%	+$3.48K	﹤0.01%	6436
2024 Q1	$7K	Buy	322 +184	+133%	+$991	﹤0.01%	6313
2023 Q4	$1K	Buy	138 +136	+6,800%	+$3.06K	﹤0.01%	6890
2023 Q3	$0	Sell	2 -4	-67%	-$179	﹤0.01%	7070
2023 Q2	$1K	Buy	6 +1	+20%	+$673	﹤0.01%	6958
2023 Q1	$2K	Buy	5 +3	+150%	+$2.36K	﹤0.01%	6749
2022 Q4	$2K	Buy	+2	New	+$2.61K	﹤0.01%	6910
2022 Q3	–	Sell	-1	Closed	-$2K	–	7430
2022 Q2	$2K	Hold	1	–	–	﹤0.01%	6915
2022 Q1	$3K	Sell	1 -4	-80%	-$10K	﹤0.01%	7374
2021 Q4	$24K	Buy	5 +3	+150%	+$18K	﹤0.01%	6714
2021 Q3	$15K	Buy	2 +1	+100%	+$8.11K	﹤0.01%	6808
2021 Q2	$12K	Hold	1	–	–	﹤0.01%	6795
2021 Q1	$13K	Hold	1	–	–	﹤0.01%	6669
2020 Q4	$7K	Buy	+1	New	+$6.95K	﹤0.01%	6518
2020 Q3	–	Hold	0	–	–	–	6605
2020 Q2	–	Hold	0	–	–	–	6610
2020 Q1	–	Sell	-1	Closed	-$10.6K	–	6396
2019 Q4	$9K	Buy	+1	New	+$10.5K	﹤0.01%	6170
2019 Q3	–	Hold	0	–	-$1K	–	6686
2019 Q2	–	Hold	0	–	–	–	6674
2018 Q4	–	Hold	0	–	–	–	6732
2018 Q3	–	Hold	0	–	–	–	6706
2018 Q2	–	Hold	0	–	–	–	6504
2018 Q1	–	Hold	0	–	–	–	6326
2017 Q4	–	Hold	0	–	–	–	6529
2017 Q3	–	Hold	0	–	–	–	6702

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Royal Bank of Canada's AVTX Position: Q2 2026 in Review

Royal Bank of Canada increased its Avalo Therapeutics (AVTX) stake by 532% in Q2 2026, buying an estimated $18.2K and bringing the position to 1,365 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #6161.

Royal Bank of Canada first reported a position in AVTX in Q4 2019 and has held it in 19 quarters since. The position peaked at $872K in Q4 2024. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Royal Bank of Canada held 1,365 shares of Avalo Therapeutics worth $26K as of Q2 2026.
Royal Bank of Canada bought 1,149 Avalo Therapeutics shares in Q2 2026, an estimated $18.2K.
Avalo Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6161 holding.
Royal Bank of Canada first reported a position in Avalo Therapeutics in Q4 2019 and has held it in 19 quarters since.
Royal Bank of Canada's Avalo Therapeutics position peaked at $872K in Q4 2024.
125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.